Table 3.

Criteria for poor-risk disease according to the EBMT CLL Transplant Consensus.28 

  • ▪ Non-response or early relapse (within 12 months) after purine analogue-containing therapy

  • ▪ Relapse (within 24 months) after purine analogue combination therapy or treatment of similar efficacy (ie, autologous stem cell transplantation)

  • ▪ p53 deletion/mutation (del 17p-) requiring treatment

 

  • ▪ Non-response or early relapse (within 12 months) after purine analogue-containing therapy

  • ▪ Relapse (within 24 months) after purine analogue combination therapy or treatment of similar efficacy (ie, autologous stem cell transplantation)

  • ▪ p53 deletion/mutation (del 17p-) requiring treatment

 
View Large